diet doctors – Diet Business Watch

Weight Watchers Collaborates With Google Health Enterprise

October 1, 2026 Weight Watchers announced a collaboration with Google Health Enterprise, combining wearable technology and AI-powered health insights with Weight Watchers’ clinical weight health program. Available now through select Weight Watchers for Business client programs, this collaboration provides employers and payers a new way to activate their weight health benefits, helping more members get […]

Weight Watchers Collaborates With Google Health Enterprise Read More »

Weight Watchers Hires New CEO

News / John LaRosa

Sept. 9, 2026 Weight Watchers announced today that it has appointed Stephen Bye as its President and CEO and a member of the company’s Board of Directors. “Bye’s appointment will become effective this fall. He most recently served as President and CEO of Ookla, a global connectivity intelligence company whose industry leading brands include Speedtest,

Weight Watchers Hires New CEO Read More »

Weight Watchers Reports Q1 2026 Results

News / John LaRosa

May 7, 2026 According to management: “We remain confident in our strategy to build the industry-leading weight health platform. Our focus is on executing high-impact initiatives that drive Clinical growth and stabilize our Behavioral business,” said Jon Volkmann, Chief Operations Officer and member of the Company’s Interim Office of the Chief Executive. “We made encouraging

Weight Watchers Reports Q1 2026 Results Read More »

New Eli Lilly Weight Loss Pill Approved – Foundayo

News / John LaRosa

April 2, 2026 On April 1, 2026, the FDA approved Foundayo (orforglipron), a new once-daily oral GLP-1 weight loss pill developed by Eli Lilly for adults with obesity or overweight and at least one weight-related condition. Unlike other options, Foundayo does not require fasting or specific timing. It mimics a natural hormone to regulate appetite and,

New Eli Lilly Weight Loss Pill Approved – Foundayo Read More »

FDA Approves Novo’s Wegovy Weight Loss Pill

News / John LaRosa

Dec. 22, 2025 The U.S. Food and Drug Administration on Dec. 22 approved a pill version of Novo Nordisk’s weight-loss drug Wegovy, the first daily oral medication for obesity treatment. The once-daily tablet — called the Wegovy pill — is the “first and only” oral GLP-1 medicine, or glucagon-like peptide-1, receptor agonists, according to Novo

FDA Approves Novo’s Wegovy Weight Loss Pill Read More »

Trump Cuts Deal To Lower Weight Loss Drug Prices

News / John LaRosa

Nov. 6, 2025 CNBC reported today that President Donald Trump announced deals with Eli Lilly and Novo Nordisk and Eli Lilly toslash the prices of some of their obesity drugs, including upcoming pills, in a landmark effort to expand access to the costly blockbuster treatment. The agreements will cut prices of so-called GLP-1 drugs for

Trump Cuts Deal To Lower Weight Loss Drug Prices Read More »

Weight Watchers Reports 3rd Qtr. Results

News / John LaRosa

Nov. 6, 2025 According to WW management: “WeightWatchers is entering a new era, uniquely positioned at the intersection of medical innovation and behavioral science, to lead this rapidly evolving weight health market,” said Tara Comonte, CEO of WeightWatchers. “GLP-1s are a breakthrough in obesity care, but real success, with or without medication, comes from combining

Weight Watchers Reports 3rd Qtr. Results Read More »

Weight Loss Pills Are On The Horizon

News / John LaRosa

Sept. 23, 2025 Soon, there may be a promising alternative for the needle-averse, as results of a recent Phase 3 trial confirmed that a daily 25-milligram semaglutide pill can trigger significant weight loss. “We all knew this was coming, and we all feel that it could potentially be a game changer in terms of adopting

Weight Loss Pills Are On The Horizon Read More »

FDA Tightens Oversight of GLP-1 Ingredients Imports

Uncategorized / John LaRosa

Sept. 9, 2025 According to Reuters, “The U.S. Food and Drug Administration is tightening oversight of imports of GLP-1 drug ingredients, used for weight loss and diabetes, amid concerns that many of the items may be adulterated and pose a safety risk. The move comes as the FDA cracks down on unapproved compounded drugs, which

FDA Tightens Oversight of GLP-1 Ingredients Imports Read More »

Medifast Reports Q2 Results – Slide Continues

News / John LaRosa

August 4, 2025 “We are working diligently to transform our business as we look to help more people achieve optimal metabolic health,” said Dan Chard, CEO of Medifast. “We’re focused on new and impactful ways to reignite coach growth and productivity through targeted initiatives that aim to enhance our offering, expand tailored client solutions, and

Medifast Reports Q2 Results – Slide Continues Read More »